CARGO Therapeutics
Surveying great inventors and businesses
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company. We are excited to be in business with you — email us at info@axialvc.com
CARGO Therapeutics, founded in 2019, develops next generation chimeric antigen receptor (CAR) T-cell therapies for cancer. The company’s lead product candidate is CRG-022, an autologous CD22-targeting CAR-T cell therapy for large B-cell lymphoma. CRG-022 is initially being developed for relapsed/refractory large B-cell lymphoma after CD19 CAR-T cell therapy, an area of high unmet need. In a Phase 1 trial by Stanford, CRG-022 achieved a 68% overall response rate and 53% complete response rate with durable responses, demonstrating potential in a patient population that currently lacks good treatment options. CARGO has an ongoing potentially pivotal Phase 2 trial of CRG-022 and plans to expand development into earlier lines of therapy.
Beyond CRG-022, CARGO is leveraging two proprietary platform technologies to develop next generation CAR T-cell therapies. The company's CD2 platform is designed to maintain CAR T-cell activation even when tumor cells lose expression of costimulatory ligands like CD58, a common resistance mechanism. The STASH platform enables multiple functional components to be efficiently engineered into CAR T cells in a homogeneous product. These platforms are being utilized in CARGO's preclinical tri-specific program, CRG-023, to address both tumor antigen loss and loss of costimulation.
A key aspect of CARGO’s strategy is developing manufacturing and analytical processes for its therapies early, with the goals of ensuring reliable supply, minimizing post-approval changes, and enabling transferability and scalability. The company has already developed its intended commercial process for CRG-022.
CAR-T has seen tremendous progress but still faces limitations like antigen escape, loss of costimulation, and manufacturing challenges. By harnessing new target antigens, engineering multifunctional CAR T cells, and developing robust manufacturing processes, CARGO aims to deliver improved patient outcomes. CARGO is a promising player. The company's success will depend on progressing CRG-022 through pivotal testing, expanding the pipeline through its technology platforms, maintaining a strong cash position, and ultimately differentiating itself enough to compete with larger, established competitors. But if executed well, CARGO has the potential to establish itself as a leading next-generation CAR-T company.
